e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
KALA BIO, Inc. - Common Stock
(NQ:
KALA
)
1.544
-0.026 (-1.69%)
Streaming Delayed Price
Updated: 11:38 AM EDT, Oct 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about KALA BIO, Inc. - Common Stock
< Previous
1
2
Next >
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
September 29, 2025
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
September 03, 2025
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
September 02, 2025
Mr. Bazemore brings over 30 years of extensive leadership experience in the biopharmaceutical industry with a focus on growing rare disease companies
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 08, 2025
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 06, 2025
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
July 09, 2025
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
July 07, 2025
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Present at Jefferies Global Healthcare Conference
May 29, 2025
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 31, 2025
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
February 26, 2025
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Announces Chief Executive Officer Transition
February 12, 2025
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Announces $10,750,000 Private Placement
December 30, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
November 27, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 08, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Announces $12,500,000 Private Placement
June 27, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Present at Jefferies Global Healthcare Conference
May 29, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 29, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
February 26, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 19, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 20, 2023
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 04, 2023
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Participate in Upcoming Investor Conferences in August
August 02, 2023
From
KALA BIO, Inc.
Via
GlobeNewswire
Kala Pharmaceuticals Announces Name Change to KALA BIO
August 02, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
Facebook
Twitter
YouTube